Objective: Selective serotonin reuptake inhibitor (SSRI) use during pregnancy incurs a low
absolute risk for major malformations; however, other adverse outcomes have been …

Background Many women of reproductive age have depression, necessitating therapy with
either a tricyclic antidepressant drug or a drug, such as fluoxetine, that inhibits the reuptake …

Estimates of the lifetime risk of major depression in women range from 10% to 25%, peaking
during the reproductive years. Today, selective serotonin-reuptake inhibitors (SSRIs) are the …

Objective Given concerns about use of psychotropic medication during pregnancy, the
authors reviewed the literature regarding the effects of prenatal exposure to psychotropic …

ContextA neonatal behavioral syndrome linked to in utero serotonin reuptake inhibitor (SRI)
exposure during the last trimester of pregnancy has been identified. The US Food and Drug …

This thoroughly revised and updated reference addresses the drugs and chemicals causing
malformations and congenital anomalies in the human fetus-comprehensively reviewing …

OBJECTIVE: Previous work suggested that first-trimester exposure to tricyclic
antidepressants or fluoxetine does not affect adversely child IQ and language development …

Objective To compare the structural growth and developmental outcome of children born to
mothers diagnosed with major depressive disorder during pregnancy who were exposed or …

Julia Flint1, Sonia Panchal2, Alice Hurrell3, Maud van de Venne4, Mary Gayed5, Karen
Schreiber6, 7, Subha Arthanari8, Joel Cunningham3, Lucy Flanders3, Louise Moore9, Amy …

Objectives To examine the relationship between antidepressant use in pregnancy and low
birth weight (LBW) and preterm birth (PTB). Data Sources and Study Selection We searched …